A Real-world Study: Analysis of the Efficacy of Antiviral Therapy in CHB Patients Over 30 Years Old, HBV DNA Positive and ALT Normal

June 5, 2026 updated by: Meifang Han, Tongji Hospital

Curative Effect Analysis of Antiviral Therapy in CHB Patients Over 30 Years Old With HBV DNA Positive and Normal ALT

This is a prospective observational study of CHB patients who have not received antiviral treatment but HBV DNA are positive.Investigators aim to explore the antiviral effect and influencing factors of patients over 30 years old with normal ALT level after receiving antiviral treatment.

Study Overview

Status

Completed

Detailed Description

In the past, clinicians thought that patients with chronic hepatitis B with normal ALT should be followed up regularly and not be treated with antiviral therapy for the time being, but more and more studies show that if antiviral therapy is not started in time, these patients still have a relatively high risk of cirrhosis and HCC. Therefore, the current Chinese guideline recommends that patients over the age of 30 with HBV DNA positive need antiviral treatment even if their ALT levels are normal. In this study, investigators aim to observe the antiviral effect of CHB patients above 30 years old and normal liver function. CHB patients were divided into NAs (TMF, ETV, or TAF) treatment and untreated groups for follow-up. Then, participants who achieved HBV DNA negative and HBsAg <3000 IU/ml after 12 weeks of NAs therapy could choose either NAs combined with 48 weeks of pegylated interferon α-2b(Peg-IFNα-2b) therapy or continue NAs monotherapy. Follow-ups were conducted every 12-24 weeks for a total duration of 96 weeks. Dynamic observations included monitoring virological markers,biochemical indicators,liver stiffness measurement(LSM),and controlled attenuation parameter(CAP) throughout the study period. After obtaining the informed consent of participants, the serum of participants and PBMC of some participants were collected for further study,so that investigators are able to explore the serological indexes related to curative effect and the immune function of participants before and after treatment.

Study Type

Observational

Enrollment (Actual)

250

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Hubei
      • Wuhan, Hubei, China, 430000
        • Tongji Hospital,Wuhan,Hubei

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

Yes

Sampling Method

Non-Probability Sample

Study Population

The research population is CHB patients who have never received antiviral treatment and come to Tongji hospital for consultation and reexamination.

Description

Inclusion Criteria:

  1. CHB patients over 30 years old ;
  2. HBV DNA >20IU/ml and ALT level ≤40U/L;
  3. All of them have never received any antiviral treatment(including NAs and interferon-α)。

Exclusion Criteria:

  1. pregnancy status;
  2. Patients with compensated/decompensated cirrhosis and liver cancer have been diagnosed by imaging or other indicators;
  3. HCV, HIV, EB virus/cytomegalovirus infection, schistosomiasis liver disease, drug-induced liver injury, autoimmune hepatitis and alcoholic liver disease;
  4. Use immunosuppressants ;
  5. Previous history of liver cancer, organ transplantation and alcoholism (male ≥30 g/d, female ≥20 g/d);
  6. Insufficient follow-up time and imperfect clinical/laboratory informations;
  7. Combined with other major diseases.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
NA treatment
NA treated with TDF,ETV OR TMF
Control group without antiviral treatment

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
48-week HBV DNA negativity rate(%)
Time Frame: 48 weeks
HBV DNA negative rate(%) at 48 weeks
48 weeks

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
48-week ALT normalization rate(%)
Time Frame: 48 weeks
ALT normalization rate(%) at 48 weeks
48 weeks

Other Outcome Measures

Outcome Measure
Measure Description
Time Frame
Degree of improvement in liver fibrosis
Time Frame: 48 weeks
Changes in liver stiffness measurement (LSM) by FibroScan were used to describe changes in patients' liver fibrosis
48 weeks

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Investigators

  • Principal Investigator: Meifang Han, Doctor, Tongji Hospital

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

March 13, 2023

Primary Completion (Actual)

March 13, 2024

Study Completion (Actual)

June 13, 2025

Study Registration Dates

First Submitted

April 13, 2026

First Submitted That Met QC Criteria

June 5, 2026

First Posted (Actual)

June 9, 2026

Study Record Updates

Last Update Posted (Actual)

June 9, 2026

Last Update Submitted That Met QC Criteria

June 5, 2026

Last Verified

June 1, 2026

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

UNDECIDED

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe